FDA
-
-
-
-
-
-
-
Cellectar reports 79% response rate in Waldenstrom cancer study
-
-
-
-
-
-
-
Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
-
-
-
-
-
-
-
Cellectar Biosciences Expands Global Intellectual Property Estate
-
-
-
-
-
-
-
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
-
-
-
-
-
-
-
Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
-
-
-
-
-
-
-
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
-
-
-
-
-
-
-
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
-
332,937 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


